Exosomal circRNAs: Novel biomarkers and therapeutic targets for urinary tumors

Liu, Qiang; Li, Shenglong

doi:10.1016/j.canlet.2024.216759

Cited by 7 publications

(2 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significance of exosomal circRNAs in cancer biology is increasingly evident, as their potential as therapeutic targets and biomarkers has attracted increased amounts of attention ( 38 , 39 ). Studies have revealed that exosomal circGDI2 regulates the malignant behaviors of oral squamous cell carcinoma cells by targeting the miR-424–5p/SCAI axis.…”

Section: The Role Of Exosomal Circrnas In the Treatment Of Squamous C...mentioning

confidence: 99%

Prospects for the clinical application of exosomal circular RNA in squamous cell carcinoma

Wang,

Jiang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) is a prevalent malignancy affecting multiple organs in the human body, including the oral cavity, esophagus, cervix, and skin. Given its significant incidence and mortality rates, researchers are actively seeking effective diagnostic and therapeutic strategies. In recent years, exosomes and their molecular cargo, particularly circular RNA (circRNA), have emerged as promising areas of investigation in SCC research. Exosomes are small vesicles released into the extracellular environment by cells that contain biomolecules that reflect the physiological state of the cell of origin. CircRNAs, known for their unique covalently closed loop structure and stability, have garnered special attention in oncology and are closely associated with tumorigenesis, progression, metastasis, and drug resistance. Interestingly, exosomal circRNAs have been identified as ideal biomarkers for noninvasive cancer diagnosis and prognosis assessment. This article reviews the progress in research on exosomal circRNAs, focusing on their expression patterns, functions, and potential applications as biomarkers in SCC, aiming to provide new insights and strategies for the diagnosis and treatment of SCC.

show abstract

Section: The Role Of Exosomal Circrnas In the Treatment Of Squamous C...mentioning

confidence: 99%

Prospects for the clinical application of exosomal circular RNA in squamous cell carcinoma

Wang,

Jiang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Functional circRNAs were initially found to efficiently sponge microRNAs, thereby regulating downstream target genes post-transcriptionally. They also serve as reservoirs or carriers for miRNAs [ 14 ]. This phenomenon is substantiated by the discovery of cerebellar degeneration-related protein (CDR1as), also known as CiRS-7 [ 15 ], opened the door to the understanding that circRNAs can compete as endogenous RNAs (ceRNA) with over 60 miRNA binding sites.…”

Section: Introductionmentioning

confidence: 99%

circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC)

Tang,

Liu,

Zhang

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

Background Recent evidence has demonstrated that abnormal expression and regulation of circular RNA (circRNAs) are involved in the occurrence and development of a variety of tumors. The aim of this study was to investigate the effects of circ_PPAPDC1A in Osimertinib resistance in NSCLC. Methods Human circRNAs microarray analysis was conducted to identify differentially expressed (DE) circRNAs in Osimertinib-acquired resistance tissues of NSCLC. The effect of circ_PPAPDC1A on cell proliferation, invasion, migration, and apoptosis was assessed in both in vitro and in vivo. Dual-luciferase reporter assay, RT-qPCR, Western-blot, and rescue assay were employed to confirm the interaction between circ_PPAPDC1A/miR-30a-3p/IGF1R axis. Results The results revealed that circ_PPAPDC1A was significantly upregulated in Osimertinib acquired resistance tissues of NSCLC. circ_PPAPDC1A reduced the sensitivity of PC9 and HCC827 cells to Osimertinib and promoted cell proliferation, invasion, migration, while inhibiting apoptosis in Osimertinib-resistant PC9/OR and HCC829/OR cells, both in vitro and in vivo. Silencing circ_PPAPDC1A partially reversed Osimertinib resistance. Additionally, circ_PPAPDC1A acted as a competing endogenous RNA (ceRNA) by targeting miR-30a-3p, and Insulin-like Growth Factor 1 Receptor (IGF1R) was identified as a functional gene for miR-30a-3p in NSCLC. Furthermore, the results confirmed that circ_PPAPDC1A/miR-30a-3p/IGF1R axis plays a role in activating the PI3K/AKT/mTOR signaling pathway in NSCLC with Osimertinib resistance. Conclusions Therefore, for the first time we identified that circ_PPAPDC1A was significantly upregulated and exerts an oncogenic role in NSCLC with Osimertinib resistance by sponging miR-30a-3p to active IGF1R/PI3K/AKT/mTOR pathway. circ_PPAPDC1A may serve as a novel diagnostic biomarker and therapeutic target for NSCLC patients with Osimertinib resistance. Graphical Abstract

show abstract